<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04907214</url>
  </required_header>
  <id_info>
    <org_study_id>210907</org_study_id>
    <nct_id>NCT04907214</nct_id>
  </id_info>
  <brief_title>SGLT2 Inhibitor Effects on Inflammation and Heart Disease in Obesity Pilot</brief_title>
  <official_title>The Effect of SGLT2 Inhibition on Adipose Tissue Inflammation and Endothelial Function Pilot</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vanderbilt University Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Vanderbilt University Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Obesity is associated with increased cardiometabolic disease risk due, in part, to heightened&#xD;
      chronic inflammation arising from adipose tissue. There are no current targeted therapies to&#xD;
      prevent or reverse the chronic inflammation of obesity, and a better understanding of these&#xD;
      inflammatory pathways in humans is key to future therapeutic interventions. This project will&#xD;
      determine both the anti-inflammatory potential of the SGLT2 inhibitor empagliflozin, and the&#xD;
      contribution of adipose inflammation to surrogate measures of cardiovascular disease in a&#xD;
      randomized controlled trial of obese patients.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date type="Actual">July 29, 2021</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in adipose pro-inflammatory T cell numbers after 3 months</measure>
    <time_frame>Baseline to 12 weeks</time_frame>
    <description>Pro-inflammatory T cells are quantified using flow cytometry</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in adipose pro-inflammatory T cell numbers after 2 weeks</measure>
    <time_frame>Baseline to 2 weeks</time_frame>
    <description>Pro-inflammatory T cells are quantified using flow cytometry</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in plasma inflammatory cytokines after 3 months</measure>
    <time_frame>Baseline to 12 weeks</time_frame>
    <description>Pro-inflammatory cytokines in plasma are quantified, including interferon-gamma, tumor necrosis factor-alpha, and interleukin-6.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in endothelium-dependent vasodilation as measured by Flow-mediated dilation after 3 months</measure>
    <time_frame>Baseline to 12 weeks</time_frame>
    <description>To assess endothelium-dependent vasodilation, brachial artery diameter is measured under basal conditions and during reactive hyperemia.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">6</enrollment>
  <condition>Obesity</condition>
  <condition>Pre-diabetes</condition>
  <arm_group>
    <arm_group_label>Empagliflozin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Individuals receive empagliflozin 25mg/day orally for 12 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Empagliflozin 25 MG</intervention_name>
    <description>Oral empagliflozin daily</description>
    <arm_group_label>Empagliflozin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:&#xD;
&#xD;
          1. Age 18 to 70 years old&#xD;
&#xD;
          2. Impaired glucose tolerance (two-hour plasma glucose 140-199 mg/dL) or impaired fasting&#xD;
             glucose (100-125mg/dL) or HbA1c 5.7-6.4%&#xD;
&#xD;
          3. BMI ≥ 30 kg/M2&#xD;
&#xD;
          4. The ability to provide informed consent&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
        Criteria Related to Medical Diagnoses/Conditions/Treatments:&#xD;
&#xD;
          1. Diabetes type 1 or type 2, as defined by a fasting plasma glucose of 126 mg/dL or&#xD;
             greater, a two-hour plasma glucose of 200 mg/dL or greater, HbA1c ≥6.5%, or the use of&#xD;
             anti-diabetic medication&#xD;
&#xD;
          2. Pregnancy or breast-feeding. Women of child-bearing potential will be required to have&#xD;
             undergone tubal ligation or to be using an oral contraceptive or barrier methods of&#xD;
             birth control&#xD;
&#xD;
          3. Cardiovascular disease such as myocardial infarction within six months prior to&#xD;
             enrollment, presence of angina pectoris, significant arrhythmia, congestive heart&#xD;
             failure (left ventricular hypertrophy acceptable), deep vein thrombosis, pulmonary&#xD;
             embolism, second or third degree heart block, mitral valve stenosis, aortic stenosis&#xD;
             or hypertrophic cardiomyopathy&#xD;
&#xD;
          4. Presence of implanted cardiac defibrillator or pacemaker&#xD;
&#xD;
          5. History of serious neurologic disease such as cerebral hemorrhage, stroke, or&#xD;
             transient ischemic attack&#xD;
&#xD;
          6. History of pancreatitis or pancreatic surgery&#xD;
&#xD;
          7. History or presence of immunological or hematological disorders&#xD;
&#xD;
          8. Clinically significant gastrointestinal impairment that could interfere with drug&#xD;
             absorption&#xD;
&#xD;
          9. History of advanced liver disease with cirrhosis&#xD;
&#xD;
         10. Individuals with an eGFR&lt;45 mL/min/1.73 m2, where eGFR is determined by the&#xD;
             four-variable Modification of Diet in Renal Disease (MDRD) equation, where serum&#xD;
             creatinine is expressed in mg/dL and age in years: eGFR (mL/min/1.73m2)=186 •&#xD;
             Scr-1.154 • age-0.203 • (0.742 if female)&#xD;
&#xD;
         11. Treatment with chronic systemic glucocorticoid therapy (more than 7 consecutive days&#xD;
             in 1 month)&#xD;
&#xD;
         12. Treatment with anticoagulants&#xD;
&#xD;
         13. Any underlying or acute disease requiring regular medication which could possibly pose&#xD;
             a threat to the subject or make implementation of the protocol or interpretation of&#xD;
             the study results difficult&#xD;
&#xD;
         14. History of alcohol abuse (&gt;14 per week for men and &gt;7 per week for women) or illicit&#xD;
             drug use&#xD;
&#xD;
         15. Treatment with any investigational drug in the one month preceding the study&#xD;
&#xD;
         16. Previous randomization in this trial&#xD;
&#xD;
         17. Mental conditions rendering a subject unable to understand the nature, scope and&#xD;
             possible consequences of the study&#xD;
&#xD;
         18. Inability to comply with the protocol in the opinion of the principal investigator,&#xD;
             e.g., uncooperative attitude, inability to return for follow-up visits, and&#xD;
             unlikelihood of completing the study&#xD;
&#xD;
             Criteria Related to Known Adverse Effects of Drug:&#xD;
&#xD;
         19. Uncircumcised men or men with history of balanitis&#xD;
&#xD;
         20. History of urinary incontinence&#xD;
&#xD;
         21. History of recurrent (&gt;3) episodes of vulvovaginitis per year, or severe symptoms&#xD;
&#xD;
         22. History of Fournier's gangrene&#xD;
&#xD;
         23. History of recurrent (≥3) UTIs per year or pyelonephritis&#xD;
&#xD;
         24. History of symptomatic hypotension or conditions predisposing to volume depletion&#xD;
&#xD;
         25. Known peripheral vascular disease, neuropathy, history of foot ulcers or lower limb&#xD;
             amputations&#xD;
&#xD;
         26. Treatment with loop diuretics furosemide, torsemide, bumetanide, ethacrynic acid&#xD;
&#xD;
         27. Known or suspected allergy to trial medications, excipients, or related products&#xD;
&#xD;
         28. Contraindications to study medications, worded specifically as stated in the product's&#xD;
             prescribing information&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mona Mashayekhi, MD/PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Vanderbilt University Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Vanderbilt University Medical Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>May 25, 2021</study_first_submitted>
  <study_first_submitted_qc>May 25, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 28, 2021</study_first_posted>
  <last_update_submitted>September 17, 2021</last_update_submitted>
  <last_update_submitted_qc>September 17, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 24, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Vanderbilt University Medical Center</investigator_affiliation>
    <investigator_full_name>Mona Mashayekhi</investigator_full_name>
    <investigator_title>Clinical Instructor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Obesity</mesh_term>
    <mesh_term>Prediabetic State</mesh_term>
    <mesh_term>Inflammation</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Empagliflozin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

